Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 312.38M P/E - EPS this Y -0.50% Ern Qtrly Grth -
Income -56.07M Forward P/E -5.21 EPS next Y 13.20% 50D Avg Chg 12.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 33.00%
Dividend N/A Price/Book 2.89 EPS next 5Y - 52W High Chg -34.00%
Recommedations 2.10 Quick Ratio 8.81 Shares Outstanding 29.65M 52W Low Chg 189.00%
Insider Own 29.17% ROA -37.42% Shares Float 19.11M Beta -0.61
Inst Own 32.51% ROE -61.81% Shares Shorted/Prior 3.02M/1.98M Price 10.68
Gross Margin - Profit Margin - Avg. Volume 118,643 Target Price 11.21
Oper. Margin - Earnings Date - Volume 52,517 Change 0.38%
About Immuneering Corporation

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Immuneering Corporation News
12/22/24 Aadi Bioscience Leads 3 Promising US Penny Stocks
12/19/24 Immuneering Launches Pancreatic Cancer Advisory Board
12/17/24 Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025
12/13/24 Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?
12/12/24 Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma
11/27/24 Immuneering to Present at the Piper Sandler 36แต—สฐ Annual Healthcare Conference
11/21/24 Immuneering Leads The Pack Of 3 US Penny Stocks To Monitor
11/13/24 Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates
10/16/24 IMRX Stock Up on FDA's Orphan Drug Tag for Pancreatic Cancer Drug
10/15/24 Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
10/14/24 Here's Why We're A Bit Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Situation
09/16/24 IMRX Stock Soars on Upbeat Efficacy Data From Pancreatic Cancer Study
09/13/24 Why Is Nanocap Immuneering Stock Trading Higher On Friday?
09/12/24 Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients
08/29/24 Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
08/28/24 Favourable Signals For Immuneering: Numerous Insiders Acquired Stock
08/06/24 Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
07/31/24 Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer
05/29/24 Immuneering to Present at the Jefferies Global Healthcare Conference
05/07/24 Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
IMRX Chatroom

User Image BiotechValues Posted - 5 hours ago

$IMRX directors opting for $2.20 stock options, in lieu of their cash retainer, directly ahead of the pancreatic cancer readout next week. Bodes well IMO https://ir.immuneering.com/node/8446/html

User Image Yio123 Posted - 9 hours ago

sorry my bad but i am doing $nrxp i left this scammer $imrx. come to $nrxp we are enjoying smooth ride

User Image Yio123 Posted - 9 hours ago

$IMRX just a strong sixth sense

User Image TradeMundi Posted - 14 hours ago

$LAES $AIRI $DHAI $IMRX

User Image JOEYBIG Posted - 1 day ago

$IMRX It's just another mis-managed biotech scam!

User Image Kobewins Posted - 12/31/24

$IMRX did thru not announce news was coming before end of 2024? That detail propelled many people to invest here. Predictions for 2024 was as high as $25 by some analysts for 2024. Iโ€™m just trying to understand what happen? Unless it was just all preplanned somehow. Now we just sit & wait as they will toast tonight to a successful year. All I can say is cheers to everyone! Hang in there.

User Image Wisegill Posted - 12/30/24

$IMRX

User Image Stocksrockman Posted - 12/28/24

$KORE worlds first 5G AI Internet Hotter than Al Gore....Ai GORE hmmm $SIDU and $IMRX still bullish $PRZO about to spike $SNES what a run

User Image Kdog125 Posted - 12/27/24

$IMRX smart ones are currently accumulating for early Jan 2025 results ๐Ÿ‘€๐Ÿ”ฅ

User Image Kdog125 Posted - 12/27/24

$IMRX

User Image Kdog125 Posted - 12/27/24

$IMRX

User Image Eyal94 Posted - 12/27/24

$IMRX

User Image JunkPost Posted - 12/27/24

$IMRX Nice come back

User Image TradeMyChart Posted - 12/26/24

$IMRX

User Image HotStockNews Posted - 12/26/24

$PBM $IMRX $CERO $AZTR $NKGN

User Image StocktwitsNews Posted - 12/26/24

Top 5 Biotech Stocks That Captured Retail Investor Interest The Most In 2024. $CERO $PBM $AZTR $IMRX $NKGN https://stevents.onelink.me/wmCS/xdk3h5rx

User Image SaintJeremiah Posted - 12/26/24

$IMRX tuned in for blastoff right now Now, now now Iโ€™m tuned in

User Image Yio123 Posted - 12/25/24

$IMRX NEXT GAP FILL BE 1.43$ THEN MAYBE IT WILL REACH 3$ ZONE UNTIL THEN NOT POSSIBLE

User Image SaintJeremiah Posted - 12/24/24

$IMRX How exciting!! Having so much FUN!!!๐Ÿคฉ

User Image itrekntravel Posted - 12/24/24

$IMRX has been clawing its way, a few cents each day. It's up 30% in 5 days. Hmmm.

User Image BiotechValues Posted - 12/24/24

$IMRX anyone ever see this quote from November? Is he hinting that the upcoming data in Jan for the FOLI arm is going to show strong data? They haven't ever released the data for that arm. https://www.cancernetwork.com/view/the-future-looks-bright-in-the-pancreatic-cancer-treatment-field

User Image JunkPost Posted - 12/24/24

$IMRX About to break out or what?

User Image Kdog125 Posted - 12/24/24

$IMRX Interesting 10K share buy at $2.18 ๐Ÿ‘€

User Image RonFarms Posted - 12/24/24

$IMRX you may like to add CADL to your watch list... PT was just raised for $11 to $19! Amazing what Ai can do for cancer drugs and saving lives!

User Image itrekntravel Posted - 12/23/24

i'm a bit bored with this one today. Let's take it to 2 and a quarter to end the day, can we $imrx?

User Image Starlord10 Posted - 12/23/24

$IMRX Double bottom pattern. Good momo. Big ass gap at $5.8 would sure be nice!

User Image itrekntravel Posted - 12/23/24

$IMRX i'm guessing the below article is behind today's mini-push. Dunno, but i'll take it.

User Image XQuise Posted - 12/23/24

$IMRX .. first half of January ๐Ÿ˜‰

User Image itrekntravel Posted - 12/23/24

https://www.prnewswire.com/news-releases/how-cutting-edge-immunotherapies-are-redefining-cancer-treatment-options-302338435.html $IMRX

User Image Eyal94 Posted - 12/23/24

$IMRX

Analyst Ratings
Needham Buy Sep 13, 24
Chardan Capital Buy Aug 7, 24
Needham Buy Aug 7, 24
Needham Buy May 8, 24
Needham Buy Apr 12, 24
Mizuho Buy Apr 2, 24
Jefferies Hold Mar 15, 24
Chardan Capital Buy Mar 15, 24
Needham Buy Mar 15, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Zeskind Benjamin J. PRESIDENT AND CEO PRESIDENT AND CEO Dec 22 Option 3.01 2,500 7,525 2,261,852 12/27/22
Bookman Michael GENERAL COUNSEL AND.. GENERAL COUNSEL AND SECRETARY May 17 Buy 4.88 1,000 4,880 2,402 05/18/22
KEATING LAURIE Director Director May 16 Buy 5 7,000 35,000 14,000 05/17/22
Amin Biren CFO, TREASURER CFO, TREASURER May 12 Buy 4.42 1,000 4,420 7,898 05/12/22
Zeskind Benjamin J. PRESIDENT AND CEO PRESIDENT AND CEO Apr 12 Option 3.01 2,000 6,020 2,259,352 04/14/22
Zeskind Benjamin J. PRESIDENT AND CEO PRESIDENT AND CEO Mar 23 Buy 8.02 3,000 24,060 2,257,352 03/24/22
Hall Brett Matthew CHIEF SCIENTIFIC OFF.. CHIEF SCIENTIFIC OFFICER Mar 23 Buy 7.91 1,050 8,306 330,134 03/23/22
Barrett Scott CHIEF MEDICAL OFFICE.. CHIEF MEDICAL OFFICER Mar 22 Buy 7.485 900 6,736 7,563 03/22/22
Feinberg Peter Director Director Mar 15 Buy 6.75 6,667 45,002 11,766 03/16/22
BERMAN ANN E Director Director Mar 15 Buy 6.40 6,000 38,400 9,500 03/15/22
Zeskind Benjamin J. PRESIDENT AND CEO PRESIDENT AND CEO Feb 28 Option 3.01 2,000 6,020 2,254,352 03/01/22